Navigation Links
Akorn, Inc. Announces Second Quarter 2009 Earnings Release and Conference Call Information
Date:7/29/2009

LAKE FOREST, Ill., July 29 /PRNewswire-FirstCall/ -- Akorn, Inc. (Nasdaq: AKRX) will release second quarter 2009 earnings Monday, August 10 after stock market close. The company will host a conference call on Tuesday, August 11 to discuss quarterly results followed by a Q&A session:

    Subject:               Akorn Second Quarter 2009 Conference Call

    Date/Time:             Tuesday, August 11, 2009 at 10:00 a.m. Eastern Time

    Domestic Callers:      (800) 289-0479

    International Callers: (913) 981-5519

URL For Webcast: http://www.videonewswire.com/event.asp?id=56168

The live broadcast of Akorn's conference call will also be available online at www.akorn.com under the investor relations tab on August 11, 2009, beginning at 10:00 a.m. (Eastern Time). The online replay will follow immediately and will be available for 30 days.

About Akorn, Inc.

Akorn, Inc. manufactures and markets sterile specialty pharmaceuticals. Akorn has manufacturing facilities located in Decatur, Illinois and Somerset, New Jersey and markets and distributes an extensive line of hospital and ophthalmic pharmaceuticals. Additional information is available at the Company's website at www.akorn.com.

This press release includes statements that may constitute "forward-looking statements", including with regard to the company's future operations and its earnings expectations. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of future operating or financial performance. Factors that could cause or contribute to such differences include, but are not limited to: statements relating to future steps we may take, prospective products, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. These cautionary statements should be considered in connection with any subsequent written or oral forward-looking statements that may be made by the company or by persons acting on its behalf and in conjunction with its periodic SEC filings. You are advised, however, to consult any further disclosures we make on related subjects in our reports filed with the SEC. In particular, you should read the discussion in the section entitled "Cautionary Statement Regarding Forward-Looking Statements" in our most recent Annual Report on Form 10-K, as it may be updated in subsequent reports filed with the SEC. That discussion covers certain risks, uncertainties and possibly inaccurate assumptions that could cause our actual results to differ materially from expected and historical results. Other factors besides those listed there could also adversely affect our results


'/>"/>
SOURCE Akorn, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Stryker Announces Election of New Director
2. Birdies for Breast Cancer Announces Fifth Annual Charity Golf Classic Hosted by Top Womens Golfer, Cristie Kerr
3. ASTRO announces 2009 Fellows
4. Smith & Nephew Announces Launch of ACTICOAT Flex Wound Care Products in the USA
5. Boston Scientific Announces Election of Katharine Bartlett and Bruce Byrnes to Its Board of Directors
6. Hillenbrand Announces Third-Quarter Earnings Release Date and Conference Call
7. Access Pharmaceuticals Announces New MuGard Commercial Strategy in North America
8. Patriot Scientific Corporation Announces Cardiac Science Corporations Purchase of a Moore Microprocessor Patent(TM) Portfolio License
9. QuatRx Announces Further Positive Phase 3 Results For Ophena(TM) (Ospemifene Tablets) in Postmenopausal Vaginal Atrophy
10. Medivation Announces Second Quarter 2009 Financial Results Teleconference and Webcast on August 5, 2009
11. HCA Announces Offering of $750 Million Senior Secured First Lien Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department ... in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at ... Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... ... ... Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair ... hour by 2020 and then adjusting it yearly to increase at the same rate as ... the wage floor does not erode again, and make future increases more predictable. , The ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: